Application of targeted therapy and immunotherapy in adjuvant and neoadjuvant therapy of hepatocellular carcinoma
10.3760/cma.j.cn115396-20220325-00098
- VernacularTitle:靶向及免疫治疗在肝细胞癌辅助和新辅助治疗中的应用
- Author:
Hangyan WANG
1
;
Dianrong XIU
Author Information
1. 北京大学第三医院普通外科，北京 100191
- Keywords:
Liver neoplasms;
Neoadjuvant therapy;
Therapeutic uses;
Hepatocellular carcinoma;
Targeted therapy;
Immunotherapy;
Neoadjuvant
- From:
International Journal of Surgery
2022;49(4):223-227
- CountryChina
- Language:Chinese
-
Abstract:
There are significant differences between eastern and western guidelines for the treatment of hepatocellular carcinoma, and the treatment of advanced liver cancer is still a major challenge. With the development of systematic therapy for hepatocellular carcinoma, these drugs have gradually moved from clinical trials to clinical practice, from second-line to first-line treatment. Up to now, we have entered the era of targeted therapy combined with immunotherapy, which provided us with new strategies for adjuvant; neoadjuvant and conversion therapy in the treatment of hepatocellular carcinoma. Hepatocellular carcinoma has a very high recurrence rate after operation. At present, there is no effective postoperative adjuvant therapy strategy to reduce recurrence. With the promoting of clinical trials, application of adjuvant therapy in selected patients based on the risk of recurrence may be the future research directions. For neoadjuvant therapy and conversion therapy, the most urgent issue may be the controversial criteria. Through further basic and clinical research, precise and individualized targeted therapy and immunotherapy for hepatocellular carcinoma is the future development direction.
